Onkologie, Hämatologie - Daten und Informationen
SitemapSitemap  


Literatur zu Kapitel 9: Periphere T-Zell-Lymphome

Autor/en: Steffen Neumann, Gerald Wulf, Lorenz Trümper
Letzte Änderung: 30.04.2011
  • Bartlett NL, Longo DL.
    T-small lymphocyte disorders.
    Semin Hematol 1999;36:164-170. PMID:10319385
    [Medline]


  • Catovsky D et al.
    Prolymphocytic leukaemia of B and T cell type.
    Lancet 1973;2:232-234. PMID:4124423
    [Medline]


  • Corradini P et al.
    Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.
    J Clin Oncol 2004;22:2172-2176. PMID:15169805
    [Medline]


  • Corradini P et al.
    Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation.
    Leukemia 2006;20:1533-1538. PMID:16871285
    [Medline]


  • Dearden CE.
    T-cell prolymphocytic leukemia.
    Med Oncol 2006;23:17-22. PMID:16645226
    [Medline]


  • Dearden CE et al.
    High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.
    Blood 2001;98:1721-1726. PMID:11535503
    [Medline]


  • Drexler HG et al.
    Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
    Leukemia 2000;14:1533-1559. PMID:10994999
    [Medline]


  • Enblad G et al.
    A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.
    Blood 2004;103:2920-2924. PMID:15070664
    [Medline]


  • Escalon MP et al.
    Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
    Cancer 2005;103:2091-2098. PMID:15816054
    [Medline]


  • Falini B et al.
    ALK+ lymphoma: clinico-pathological findings and outcome.
    Blood 1999;93:2697-2706. PMID:10194450
    [Medline]


  • Gallamini A et al.
    Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.
    Blood 2007;110:2316-2323. PMID:17581918
    [Medline]


  • Ginaldi L et al.
    Differential expression of CD3 and CD7 in T-cell malignancies: a quantitative study by flow cytometry.
    Br J Haematol 1996;93:921-927. PMID:8703826
    [Medline]


  • Gisselbrecht C et al.
    Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA).
    Blood 1998;92:76-82. PMID: 9639502
    [Medline]


  • Gisselbrecht C et al.
    Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma.
    J Clin Oncol 2002;20:2472-2479. PMID:12011124
    [Medline]


  • Glaser KB.
    HDAC inhibitors: Clinical update and mechanism-based potential.
    Biochem Pharmacol 2007;74:659-671. PMID:17498667
    [Medline]


  • Haioun C et al.
    Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - a groupe d'Etude des lymphomes de l'Adulte study.
    J Clin Oncol 2000;18:3025-3030. PMID:10944137
    [Medline]


  • Hale G et al.
    Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement.
    Blood 1983;62:873-882. PMID:6349718
    [Medline]


  • Hale G. et al.
    CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Bone Marrow Transplant 2000;26:69-76. PMID:10918407
    [Medline]


  • Harris NL et al.
    World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997.
    J Clin Oncol 1999;17:3835-3849. PMID:10577857
    [Medline]


  • Hoelzer D et al.
    Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia.
    Blood 2002;99:4379-4385. PMID:12036865
    [Medline]


  • Huang HQ et al.
    Clinical outcomes of 106 patients with peripheral T-cell lymphoma treated by standard CHOP regimen.
    Ai Zheng 2004;23, Suppl:1443-1447. PMID:15566653
    [Medline]


  • International T cell lymphoma project.
    International peripheral T cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.
    J Clin Oncol 2008;26:4124-4130. PMID: 18626005
    [Medline]


  • Jaffe ES.
    The 2008 WHO classification of lymphomas: implications for clinical practice and translational research.
    Hematology, Am Soc Hematol Educ Program 2009;523-531. PMID: 20008237
    [Medline]


  • Jaffe ES.
    Lymphoid lesions of the head and neck: a model of lymphocyte homing and lymphomagenesis.
    Mod Pathol 2002;15(3):255-263. PMID:11904341
    [Medline]


  • Jaffe ES.
    Nasal and nasal-type T/NK cell lymphoma: a unique form of lymphoma associated with the Epstein-Barr virus.
    Histopathology 1995;27:581-583. PMID:8838342
    [Medline]


  • Jantunen E et al.
    High-dose therapy supported by autologous stem cell transplantation in patients with enteropathy-associated T-cell lymphoma.
    Leuk Lymphoma 2003;44:2163-2164. PMID:14959866
    [Medline]


  • Kadin ME, Carpenter C.
    Systemic and primary cutaneous anaplastic large cell lymphomas.
    Semin Hematol 2003;40:244-256. PMID: 12876673
    [Medline]


  • Keating MJ et al.
    Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.
    J Clin Oncol 2002;20:205-213. PMID:11773171
    [Medline]


  • Keating MJ et al.
    Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
    Blood 2002;99:3554-3561. PMID:11986207
    [Medline]


  • Kim JG et al.
    Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study.
    Cancer Chemother Pharmakol 2007;60(1):129-134. PMID: 17406867
    [Medline]


  • Kim MK et al.
    High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.
    Ann Hematol 2007;86:435-442. PMID:17256144
    [Medline]


  • Kluin PM et al.
    Peripheral T/NK-cell lymphoma: a report of the IXth Workshop of the European Association for Haematopathology.
    Histopathology 2001;38:250-270. PMID:11260307
    [Medline]


  • Kurzrock R.
    Therapy of T cell lymphomas with pentostatin.
    Ann N Y Acad Sci 2001;941:200-205. PMID: 11594574
    [Medline]


  • Kutok JL, Aster JC.
    Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma.
    J Clin Oncol 2002;20:3691-3702. PMID:12202671
    [Medline]


  • Kyriakou C et al.
    High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    J Clin Oncol 2008;26(2):218-24. PMID:18182664
    [Medline]


  • Lau GK et al.
    Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.
    Gastroenterology 2003;125:1742-1749. PMID:14724827
    [Medline]


  • Lundin J et al.
    Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
    Blood 2002;100:768-773. PMID:12130484
    [Medline]


  • Matutes E et al.
    Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia.
    Blood 1991;78:3269-3274. PMID:1742486
    [Medline]


  • Mounier N et al.
    All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
    Ann Oncol 2004;15:1790-1797. PMID:15550584
    [Medline]


  • O'Brien SM, Keating MJ, Mocarski ES.
    Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
    Clin Lymphoma Myeloma 2006;7:125-130. PMID:17026823
    [Medline]


  • O'Connor OA et al.
    Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.
    J Clin Oncol 2009;27(26):4357-4364. PMID:19652067
    [Medline]


  • Guidelines on the diagnosis and management of chronic lymphocytic leukaemia.
    Br J Haematol 2004;125:294-317. PMID:15086411
    [Medline]


  • Osterborg A et al.
    Strategies in the management of alemtuzumab-related side effects.
    Semin Oncol 2006;33, Suppl 5:29-35. PMID:16720201
    [Medline]


  • Pautier P et al.
    Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature.
    Leuk Lymphoma 1999;32:545-552. PMID:10048427
    [Medline]


  • Pawson R et al.
    Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
    J Clin Oncol 1997;15:2667-2672. PMID:9215839
    [Medline]


  • Piccaluga PP et al.
    Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets.
    J Clin Invest 2007;117:823-834. PMID:17304354
    [Medline]


  • Piccaluga PP et al.
    Expression of CD52 in peripheral T-cell lymphoma.
    Haematologica 2007;92:566-567. PMID:17488672
    [Medline]


  • Rai KR et al.
    Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
    J Clin Oncol 2002;20:3891-3897. PMID:12228210
    [Medline]


  • Reimer P et al.
    Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study.
    J Clin Oncol 2009;27(1):106-113: PMID:19029417
    [Medline]


  • Reimer P et al.
    Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study.
    Hematol J 2004;5:304-311. PMID:15297846
    [Medline]


  • Reiser M et al.
    T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors.
    Leuk Lymphoma 2002;43:805-811. PMID:12153168
    [Medline]


  • Riechmann L et al.
    Reshaping human antibodies for therapy.
    Nature 1988;332:323-327. PMID:3127726
    [Medline]


  • Rimokh R et al.
    A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma ('Ki-1 lymphoma').
    Br J Haematol 1989;71:31-36. PMID:2917127
    [Medline]


  • Rodig SJ et al.
    Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
    Clin Cancer Res 2006;12:7174-7179. PMID:17145843
    [Medline]


  • Rodriguez J et al.
    Impact of high-dose chemotherapy on peripheral T-cell lymphomas.
    J Clin Oncol 2001;19:3766-3770. PMID:11533100
    [Medline]


  • Rodriguez J et al.
    High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy.The GEL-TAMO experience.
    Haematologica 2003;88:1372-1377. PMID:14687990
    [Medline]


  • Rodriguez J et al.
    High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience.
    Ann Oncol 2003;14:1768-1775. PMID:14630683
    [Medline]


  • Rodriguez J et al.
    Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.
    Eur J Haematol 2007;78:290-296. PMID:17378891
    [Medline]


  • Rodriguez J et al.
    Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group.
    Eur J Haematol 2007;79:32-38. PMID:17598836
    [Medline]


  • Rudiger T et al.
    Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma), results from the Non-Hodgkin's Lymphoma Classification Project.
    Ann Oncol 2002;13:140-149. PMID:11863096
    [Medline]


  • Rudiger T et al.
    Peripheral NK/T-cell lymphoma.
    Pathologe 2007;28:55-58. PMID:17195040
    [Medline]


  • Salisbury JR et al.
    Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.
    J Clin Pathol 1994;47:313-317. PMID:8027367
    [Medline]


  • Sallah S, Wan JY, Nguyen NP.
    Treatment of refractory T-cell malignancies using gemcitabine.
    Br J Haematol 2001;113:185-187. PMID:11328299
    [Medline]


  • Savage KJ.
    Peripheral T-cell lymphomas.
    Blood Rev 2007;21:201-216. PMID:17512649
    [Medline]


  • Savage KJ et al.
    Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification.
    Ann Oncol 2004;15:1467-1475. PMID:15367405
    [Medline]


  • Schetelig J et al.
    Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation.
    Haematologica 2003;88:1272-1278. PMID:14607756
    [Medline]


  • Song KW et al.
    Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype.
    Br J Haematol 2003;120:978-985. PMID:12648067
    [Medline]


  • Stein H et al.
    The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells.
    Blood 1985;66:848-858. PMID:3876124
    [Medline]


  • Stein H et al.
    CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.
    Blood 2000;96:3681-3695. PMID:11090048
    [Medline]


  • Tsimberidou AM et al.
    Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series.
    Cancer 2004;100:342-349. PMID:14716770
    [Medline]


  • Vasconcelles MJ et al.
    Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections.
    Biol Blood Marrow Transplant 2000;6:35-43. PMID:10707997
    [Medline]


  • Waldmann H.
    A personal history of the CAMPATH-1H antibody.
    Med Oncol 2002;19 Suppl:3-9. PMID:12180490
    [Medline]


  • Waldmann H, Hale G.
    CAMPATH: from concept to clinic.
    Philos Trans R Soc Lond B Biol Sci 2005;360:1707-1711. PMID: 16147535
    [Medline]


  • Weidmann E et al.
    A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.
    Leuk Lymphoma 2010;51(3):447-455. PMID:20141439
    [Medline]


  • Weisenburger DD et al.
    Systemic anaplastic large-cell lymphoma: results from the non-Hodgkin's lymphoma classification project.
    Am J Hematol 2001;67:172-178. PMID:11391714
    [Medline]


  • Wing MG et al.
    Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.
    J Clin Invest 1996;98:2819-2826. PMID:8981930
    [Medline]


  • Worth LJ, Thursky KA.
    Cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab: prophylaxis vs. pre-emptive strategies for prevention.
    Leuk Lymphoma 2006;47:2435-2436. PMID:


  • Wulf GG et al.
    Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma.
    Bone Marrow Transplant 2005;36:271-273. PMID:15937499
    [Medline]


  • Yeung CH et al.
    Epididymal secretion of CD52 as measured in human seminal plasma by a fluorescence immunoassay.
    Mol Hum Reprod 1998;4:447-451. PMID:9665631
    [Medline]


  • Zhang Y et al.
    Chromosome aberrations are restricted to the CD56+, CD3- tumour cell population in natural killer cell lymphomas: a combined immunophenotyping and FISH study.
    Br J Haematol 1999;105:737-742. PMID:10354139
    [Medline]


  • Zinzani PL et al.
    Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.
    Ann Oncol 1998;9:1351-1353. PMID:9932168
    [Medline]


Bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag"; Publikation als Buch: Deutscher Ärzte-Verlag  Deutscher Ärzte-Verlag [Mehr]
Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch:
mehr 
[Mehr]